TY - JOUR
T1 - BAI1 orchestrates macrophage inflammatory response to HSV infection-implications for oncolytic viral therapy
AU - Bolyard, Chelsea
AU - Meisen, W. Hans
AU - Banasavadi-Siddegowda, Yeshavanth
AU - Hardcastle, Jayson
AU - Yoo, Ji Young
AU - Wohleb, Eric S.
AU - Wojton, Jeffrey
AU - Yu, Jun Ge
AU - Dubin, Samuel
AU - Khosla, Maninder
AU - Xu, Bo
AU - Smith, Jonathan
AU - Alvarez-Breckenridge, Christopher
AU - Pow-Anpongkul, Pete
AU - Pichiorri, Flavia
AU - Zhang, Jianying
AU - Old, Matthew
AU - Zhu, Dan
AU - Van Meir, Erwin G.
AU - Godbout, Jonathan P.
AU - Caligiuri, Michael A.
AU - Yu, Jianhua
AU - Kaur, Balveen
N1 - Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Purpose: Brain angiogenesis inhibitor (BAI1) facilitates phagocytosis and bacterial pathogen clearance by macrophages; however, its role in viral infections is unknown. Here, we examined the role of BAI1, and its N-terminal cleavage fragment (Vstat120) in antiviral macrophage responses to oncolytic herpes simplex virus (oHSV). Experimental Design: Changes in infiltration and activation of monocytic and microglial cells after treatment of glioma-bearing mice brains with a control (rHSVQ1) or Vstat120-expressing (RAMBO) oHSV was analyzed using flow cytometry. Co-culture of infected glioma cells with macrophages or microgliawas used to examine antiviral signaling. Cytokine array gene expression and Ingenuity Pathway Analysis (IPA) helped evaluate changes in macrophage signaling in response to viral infection. TNFα-blocking antibodies andmacrophages derived from Bai1-/- mice were used. Results: RAMBO treatment of mice reduced recruitment and activation of macrophages/microglia in mice with brain tumors, and showed increased virus replication compared with rHSVQ1. Cytokine gene expression array revealed that RAMBO significantly altered the macrophage inflammatory response to infected glioma cells via altered secretion of TNFα. Furthermore, we showed that BAI1 mediated macrophage TNFα induction in response to oHSV therapy. Intracranial inoculation of wild-type/RAMBO virus in Bai1-/- or wild-type non-tumor-bearing mice revealed the safety of this approach. Conclusions: We have uncovered a new role for BAI1 in facilitating macrophage anti-viral responses. We show that arming oHSV with antiangiogenic Vstat120 also shields them from inflammatory macrophage antiviral response, without reducing safety.
AB - Purpose: Brain angiogenesis inhibitor (BAI1) facilitates phagocytosis and bacterial pathogen clearance by macrophages; however, its role in viral infections is unknown. Here, we examined the role of BAI1, and its N-terminal cleavage fragment (Vstat120) in antiviral macrophage responses to oncolytic herpes simplex virus (oHSV). Experimental Design: Changes in infiltration and activation of monocytic and microglial cells after treatment of glioma-bearing mice brains with a control (rHSVQ1) or Vstat120-expressing (RAMBO) oHSV was analyzed using flow cytometry. Co-culture of infected glioma cells with macrophages or microgliawas used to examine antiviral signaling. Cytokine array gene expression and Ingenuity Pathway Analysis (IPA) helped evaluate changes in macrophage signaling in response to viral infection. TNFα-blocking antibodies andmacrophages derived from Bai1-/- mice were used. Results: RAMBO treatment of mice reduced recruitment and activation of macrophages/microglia in mice with brain tumors, and showed increased virus replication compared with rHSVQ1. Cytokine gene expression array revealed that RAMBO significantly altered the macrophage inflammatory response to infected glioma cells via altered secretion of TNFα. Furthermore, we showed that BAI1 mediated macrophage TNFα induction in response to oHSV therapy. Intracranial inoculation of wild-type/RAMBO virus in Bai1-/- or wild-type non-tumor-bearing mice revealed the safety of this approach. Conclusions: We have uncovered a new role for BAI1 in facilitating macrophage anti-viral responses. We show that arming oHSV with antiangiogenic Vstat120 also shields them from inflammatory macrophage antiviral response, without reducing safety.
UR - http://www.scopus.com/inward/record.url?scp=85017024450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017024450&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-16-1818
DO - 10.1158/1078-0432.CCR-16-1818
M3 - Article
C2 - 27852701
AN - SCOPUS:85017024450
SN - 1078-0432
VL - 23
SP - 1809
EP - 1819
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 7
ER -